Sodium–Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease
Authors: Lurit Bepo, Anil N. Makam, Oanh Kieu Nguyen
Journal: Annals of Internal Medicine (2022)

LettersJanuary 2022Sodium–Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular DiseaseLurit Bepo, MD, MPH, Anil N. Makam, MD, MAS, Oanh Kieu Nguyen, MD, MASLurit Bepo, MD, MPHDepartment of Medicine, San Francisco General Hospital, University of California, San Francisco, CaliforniaSearch for more papers by this author, Anil N. Makam, MD, MASDepartment of Medicine, San Francisco General Hospital, University of California, San Francisco, CaliforniaSearch for more papers by this author, Oanh Kieu Nguyen, MD, MASDepartment of Medicine, San Francisco General Hospital, University of California, San Francisco, CaliforniaSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L21-0707 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:We read Patorno and colleagues' article (1) with interest. The 2021 update to the American Diabetes Association guidelines on pharmacologic approaches to glycemic treatment in type 2 diabetes (T2D) recommends the use of a sodium–glucose cotransporter-2 (SGLT2) inhibitor or glucagon-like peptide-1 receptor agonist (GLP-1 RA) with “demonstrated cardiovascular benefit” in patients with T2D who have established atherosclerotic cardiovascular disease (CVD) or indicators of high risk for this condition (2). All 7 existing cardiovascular outcome trials on GLP-1 RAs showed noninferiority compared with placebo; however, only specific GLP-1 RA drugs homologous with human GLP-1 (that is, liraglutide, subcutaneous ...References1. Patorno E, Htoo PT, Glynn RJ, et al. Sodium–glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists and the risk for cardiovascular outcomes in routine care patients with diabetes across categories of cardiovascular disease. Ann Intern Med. 2021;174:1528-41. [PMID: 34570599] doi:10.7326/M21-0893 LinkGoogle Scholar2. American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2021. Diabetes Care. 2021;44:S111-24. [PMID: 33298420] doi:10.2337/dc21-S009 CrossrefMedlineGoogle Scholar3. Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7:776-85. [PMID: 31422062] doi:10.1016/S2213-8587(19)30249-9 CrossrefMedlineGoogle Scholar4. Holman RR, Bethel MA, Mentz RJ, et al; EXSCEL Study Group. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377:1228-39. [PMID: 28910237] doi:10.1056/NEJMoa1612917 CrossrefMedlineGoogle Scholar5. Pfeffer MA, Claggett B, Diaz R, et al; ELIXA Investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247-57. [PMID: 26630143] doi:10.1056/NEJMoa1509225 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Department of Medicine, San Francisco General Hospital, University of California, San Francisco, CaliforniaDisclosures: Authors have reported no disclosures of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L21-0707. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoSodium–Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease Elisabetta Patorno , Phyo T. Htoo , Robert J. Glynn , Sebastian Schneeweiss , Deborah J. Wexler , Ajinkya Pawar , Lily G. Bessette , Kristyn Chin , Brendan M. Everett , and Seoyoung C. Kim Sodium–Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease Elisabetta Patorno , Phyo T. Htoo , Brendan M. Everett , and Seoyoung C. Kim Sodium–Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease Elisabetta Patorno , Phyo T. Htoo , Robert J. Glynn , Sebastian Schneeweiss , Deborah J. Wexler , Ajinkya Pawar , Lily G. Bessette , Kristyn Chin , Brendan M. Everett , and Seoyoung C. Kim Sodium–Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease Mei Qiu Metrics January 2022Volume 175, Issue 1Page: W3KeywordsCardiovascular diseasesCohort studiesDrugsHeart failureHemorrhagic strokeHospital medicineIschemic strokeMortalityMyocardial infarctionPopulation statistics ePublished: 18 January 2022 Issue Published: January 2022 Copyright & PermissionsCopyright © 2022 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...